2021
Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on BCR-ABL1-like subtype
HRABOVSKÝ, Štěpán, Zuzana VRZALOVÁ, Jiří ŠTIKA, H. JELINKOVA, Marie JAROŠOVÁ et. al.Základní údaje
Originální název
Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on BCR-ABL1-like subtype
Autoři
HRABOVSKÝ, Štěpán (203 Česká republika, domácí), Zuzana VRZALOVÁ (203 Česká republika, domácí), Jiří ŠTIKA (203 Česká republika, domácí), H. JELINKOVA, Marie JAROŠOVÁ (203 Česká republika, domácí), Veronika NAVRKALOVÁ (203 Česká republika, domácí), Jiří MARTENEK (203 Česká republika, domácí), František FOLBER (203 Česká republika, domácí), C. SALEK, JM. HORACEK, Šárka POSPÍŠILOVÁ (203 Česká republika, garant, domácí), Jiří MAYER (203 Česká republika, domácí) a Michael DOUBEK (203 Česká republika, domácí)
Vydání
Acta Oncologica, ABINGDON, TAYLOR & FRANCIS LTD, 2021, 0284-186X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.311
Kód RIV
RIV/00216224:14740/21:00119832
Organizační jednotka
Středoevropský technologický institut
UT WoS
000631403300001
Klíčová slova anglicky
B-other acute lymphoblastic leukemia; adults; BCR-ABL1-like; IKZF1; (plus); next-generation sequencing
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 10. 2024 14:07, Ing. Martina Blahová
Anotace
V originále
Introduction BCR-ABL1-like acute lymphoblastic leukemia (ALL) is a high-risk disease with a complex genomic background. Though extensively studied, data on the frequency and mutual associations of present mutations are still incomplete in adult patients. This retrospective study aims to map the genomic landscape of B-other ALL in a cohort of adult patients with a focus on the BCR-ABL1-like ALL subtype. Methods We analyzed bone marrow and peripheral blood samples of adult B-other ALL patients treated consecutively at three major Czech teaching hospitals. Samples were analyzed by cytogenetic methods, gene expression profiling, multiplex ligation-dependent probe amplification (MLPA), and next-generation sequencing (NGS). Results Fifty-eight B-other ALL patients (not BCR-ABL1, KMT2A-rearranged, ETV6-RUNX1, TCF3-PBX1, or iAMP21) were included in the study. Median follow-up was 23.8 months. Samples from 33 patients were available for a gene expression analysis, 48.9% identified as BCR-ABL1-like ALL. Of the BCR-ABL1-like ALL cases, 18.8% harbored IGH-CRLF2 and 12.5% P2RY8-CRLF2 fusion gene. We observed a higher MRD failure rate in BCR-ABL1-like than in non-BCR-ABL1-like ALL patients after the induction treatment (50.0 vs. 13.3%, p=.05). There was a trend to worse progression-free and overall survival in the BCR-ABL1-like group, though not statistically significant. Deletions in IKZF1 gene were found in 31.3% of BCR-ABL1-like cases. Patients with concurrent IKZF1 and CDKN2A/B, PAX5 or PAR1 region deletions (IKZF1 (plus) profile) had significantly worse progression-free survival than those with sole IKZF1 deletion or IKZF1 wild-type (p=.02). NGS analysis was performed in 54 patients and identified 99 short variants in TP53, JAK2, NRAS, PAX5, CREBBP, NF1, FLT3, ATM, KRAS, RUNX1, and other genes. Seventy-five of these gene variants have not yet been described in B-cell precursor ALL to date. Conclusion This study widens existing knowledge of the BCR-ABL1-like and B-other ALL genomic landscape in the adult population, supports previous findings, and identifies a number of novel gene variants.
Návaznosti
LQ1601, projekt VaV |
| ||
MUNI/A/1595/2020, interní kód MU |
| ||
NV19-03-00091, projekt VaV |
| ||
TN01000013, projekt VaV |
| ||
90132, velká výzkumná infrastruktura |
|